Stay updated on Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    The page revision was updated from v3.5.4 to v3.5.5, indicating a new version of the page. This likely reflects minor updates to layout or metadata, while the core study details remain unchanged.
    Difference
    0.0%
    Check dated 2026-06-09T14:48:08.000Z thumbnail image
  2. Check
    7 days ago
    Change Detected
    Summary
    Updated the Ukraine location entries to use Kharkiv Oblast and Kharkiv, Kharkiv Oblast, Ukraine, 61024 instead of the previous Kharkivs’ka Oblast’ naming.
    Difference
    0.0%
    Check dated 2026-06-02T14:01:09.000Z thumbnail image
  3. Check
    14 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    A new revision tag v3.5.4 was added, replacing the prior v3.5.3 to indicate a minor administrative update to the page documentation.
    Difference
    0.0%
    Check dated 2026-05-19T09:46:37.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    A new revision tag (v3.5.3) appears, replacing v3.5.2 and indicating a page-level update rather than changes to study details.
    Difference
    0.0%
    Check dated 2026-04-27T20:13:46.000Z thumbnail image
  6. Check
    50 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2. No visible changes to page content or layout.
    Difference
    0.0%
    Check dated 2026-04-20T16:30:39.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    Padova, PD, Italy, 35128 was added as a study location and later removed. A Lancet Oncology publication reference for MIRASOL (with an Erratum) was added and later removed.
    Difference
    0.0%
    Check dated 2026-04-06T08:45:00.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial page.